Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
EVOLVE-MS-1 study: ALKS 8700 shows promise for RRMS
- Author:
- Sharon Worcester
LOS ANGELES – ALKS 8700, a novel prodrug of monomethyl fumarate, looks promising as an oral, disease-modifying treatment for RRMS.
News
Simplified HCT-CI better predicts outcomes in young patients
- Author:
- Sharon Worcester
NEWPORT BEACH, CALIF. – A revised HCT-CI for adolescents and young adults is useful for predicting nonrelapse mortality in this specific...
News
Genetic markers may help predict allogeneic SCT outcomes
- Author:
- Sharon Worcester
SALT LAKE CITY – The presence of p2X7 SNPs could be incorporated into disease risk models to improve transplant decision making.
News
Study shows value of pretransplant assessment of function, endurance
- Author:
- Sharon Worcester
SALT LAKE CITY – Pre-allogeneic HCT assessment of functional status and endurance provides important insights into posttransplant outcomes.
News
Coming soon: CAR T-cell approvals in multiple myeloma
- Author:
- Sharon Worcester
CAR T-cell approvals for multiple myeloma are on the horizon and will transform oncology, according to Dr. Carl June.
News
Checkpoint inhibition after HiDAC shows promise in AML
- Author:
- Sharon Worcester
NEWPORT BEACH, CALIF. – Adding pembrolizumab after high-dose cytarabine in relapsed/refractory AML was safe and feasible.
News
5- and 10-day decitabine go head-to-head in poor-risk AML
- Author:
- Sharon Worcester
NEWPORT BEACH, CALIF. – Researchers directly compared 5- and 10-day decitabine in poor-risk older adults with previously untreated AML in a...
News
Study: Stick with TMP-SMX for posttransplant PJP prophylaxis
- Author:
- Sharon Worcester
NEWPORT BEACH, CALIF. – Use of atovaquone or pentamidine for post-HSCT PJP prophylaxis was associated with an increased incidence of nocardiosis...
News
ERAS reduced opioid use, improved same-day discharge after gyn surgery
- Author:
- Sharon Worcester
ORLANDO – ERAS implementation improves multiple outcomes for gynecologic surgery patients, but was associated with a slight increase in...
News
Study: Preop EKGs have little utility for benign hysterectomy
- Author:
- Sharon Worcester
ORLANDO – Preoperative EKGs had no effect on management or complications in women undergoing benign hysterectomy at a single medical center.
News
FDA orders new restrictions on sale, distribution of Essure
- Author:
- Sharon Worcester
The FDA has restricted the Essure contraception device to providers and facilities that inform patients about its risks and benefits.
News
Fast-track catheter management offers little benefit after benign hysterectomy
- Author:
- Sharon Worcester
ORLANDO – Fast-track catheter management after benign surgery reduced catheter dwell time, but did not significantly improve outcomes or patient...
News
Study: No increased risk of serious AEs with combined urogyn/gyn onc surgery
- Author:
- Sharon Worcester
ORLANDO – Concurrent urogynecologic/gynecologic oncology surgery does not increase the risk of adverse events and should be offered to appropriate...
News
Checkpoint inhibition less toxic than antiangiogenic therapy in NSCLC
- Author:
- Sharon Worcester
ORLANDO – Checkpoint blockade associated with less combined direct and indirect toxicity, a systematic review and meta-analysis suggests.
News
HDAC inhibition may boost immune therapy efficacy in breast cancer
- Author:
- Sharon Worcester
ORLANDO – Entinostat and nivolumab with or without ipilimumab showed encouraging activity in early results from a phase 1 trial of patients with...